Early pharmacokinetic studies of metronidazole (MTZ) for women with trichomoniasis have demonstrated that a single 2-g dose should maintain trichomonacidal concentrations for up to 48 hours. However, some patients receiving this dose experience treatment failure despite T. vaginalis being fully susceptible to MTZ in vitro.
In an article to be published in the November 2019 issue of Sexually Transmitted Diseases, authors Davey Legendre, PharmD (Comprehensive Pharmacy Services), Christina A. Muzny, MD, MSPH and Patricia Kissinger, PhD explore the superior efficacy of multidose MTZ therapy among women with trichomoniasis. The commentary in the article is scheduled to be discussed in the upcoming Center for Disease Control guidelines on trichomoniasis, and the conclusions are expected to generate additional research into dosing schemes. Congratulations to Davy Legendre for his important contributions to this article and expertise on the issue. Read the full article here: